Teva expects to use the net proceeds from the offerings, together with cash on hand, (i) to fund the announced tender offers to purchase, for cash, its 7.125% Senior Notes due 2025, 6.000% Senior Notes due 2025, 4.500% Senior Notes due 2025, 2.800% Senior Notes due 2023, 6.000% Senior Notes due 2024 and 3.150% Senior Notes due 2026 for a maximum combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2,250,000,000, (ii) to pay fees and expenses in connection therewith and (iii) to the extent of any remaining proceeds, the repayment of outstanding debt upon maturity, tender offer or earlier redemption. Net proceeds may be temporarily invested pending application for their stated purpose.
The Notes will be unsecured senior obligations of the Issuers and will be unconditionally guaranteed on a senior basis by Teva.
CNH Streamlines Senior Leadership Structure; Scott W. Wine As Chief Executive Officer, Oddone Incisa As Chief Financial Officer, Effective Immediately
CNH streamlines Senior Leadership structureBasildon, January 9, 2024CNH announces a streamlining of its leadership structure.Effective immediately, the Company is reducing the size of and realigning the Senior Leadership
